Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report)'s stock price fell 8.9% during trading on Monday . The stock traded as low as $13.07 and last traded at $13.26. 220,614 shares changed hands during trading, a decline of 72% from the average session volume of 795,165 shares. The stock had previously closed at $14.56.
Wall Street Analyst Weigh In
KROS has been the subject of a number of research reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Wedbush reissued an "outperform" rating and set a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. HC Wainwright cut their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a research note on Friday, December 13th. Oppenheimer cut their target price on shares of Keros Therapeutics from $102.00 to $63.00 and set an "outperform" rating for the company in a research note on Monday, December 16th. Finally, Scotiabank cut their target price on shares of Keros Therapeutics from $77.00 to $44.00 and set a "sector outperform" rating for the company in a research note on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $75.00.
View Our Latest Stock Report on KROS
Keros Therapeutics Trading Down 12.0 %
The company's 50 day moving average is $40.77 and its 200 day moving average is $48.11. The stock has a market capitalization of $519.30 million, a price-to-earnings ratio of -2.46 and a beta of 1.43.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business's revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.33) EPS. Analysts anticipate that Keros Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.
Institutional Trading of Keros Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV lifted its holdings in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock valued at $77,000 after buying an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Keros Therapeutics in the third quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics in the second quarter valued at approximately $128,000. Finally, LMR Partners LLP acquired a new position in shares of Keros Therapeutics in the third quarter valued at approximately $213,000. Hedge funds and other institutional investors own 71.56% of the company's stock.
Keros Therapeutics Company Profile
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
See Also
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
